19
Dec

ImmunoGen watched its shares fall by 50% when partner Roche revealed disappointing results for the pair’s targeted cancer drug, casting doubts on the biotech’s technology for creating armed antibodies.

…read more

Source: ImmunoGen plummets as its Roche-partnered cancer drug comes up short

    

0 No comments